RedHill Biopharma Ltd. announced the appointment of June S. Almenoff, M.D., Ph.D. and Theresa M. Stevens, J.D., M.S. to its Advisory Board. Dr. Almenoff recently served as President, Principal Executive Officer and Chief Medical Officer of Furiex Pharmaceuticals. Dr. Almenoff is currently an independent biopharma consultant and Board Director: she is Executive Chair of RDD Pharma and a member of the Boards of Ohr Pharmaceuticals and Valanbio.

She also serves as an Executive-in-Residence at Hatteras Ventures. Ms. Stevens previously served as Chief Corporate Development Officer and Senior Vice President at Aptalis Pharma (now Actavis plc). Ms. Stevens previously served as Vice President U.S. Business Development & Licensing at Novartis Pharmaceuticals Corp.

and was a member of the company's Executive Committee and its Worldwide Executive Group. Ms. Stevens currently serves as Chief Corporate Development Officer at Bioblast Pharma.